Promega, CS3368A28, HIV HiBiT-PsVLP Bioassay

HIV HiBiT-PsVLP Bioassay: Measure Viral Neutralization With Ease
Neutralizing antibodies, whether generated through vaccination or produced as therapeutic monoclonal antibodies, are critical for stopping acute and chronic viral infections. Viruses like HIV are important targets for researchers developing vaccines, prophylactic monoclonal antibodies or small-molecule inhibitors, and they need to determine the neutralizing capacity of their therapeutic. However, current methods like PRNT or PNA require infection-competent virus, stringent biosafety measures and cannot be readily implemented in most laboratories.
The HIV HiBiT-PsVLP Bioassay is a simple, easily implemented, robust system that can be used to measure the viral neutralization activity of both antibody and small-molecule inhibitors that block viral entry into target cells. The assay consists of an HIV PsVLP and a target cell line that each contain one piece of a split luciferase technology to provide a low-background and convenient luminescent readout.